Objective: To describe HIV-1 DNA levels from baseline (W0) to week 52 (W52) among patients receiving either interleukin-2 (IL-2) + optimized background therapy (OBT) or OBT as salvage treatment.
Introduction
The cell-associated HIV DNA level reflects the cellular HIV reservoir. At baseline, it is a prognostic marker of response to combined antiretroviral treatment among chronically infected patients, independent of HIV RNA levels. 1, 2 Data are scarce in highly immunocompromised patients since previous studies mostly concerned patients with HIV RNA load ,3 log 10 copies/mL. 3, 4 We aimed to determine the cell-associated HIV-1 DNA load in immunocompromised multi-experienced patients with high HIV RNA load and any association of HIV DNA level change and CD4 T cell changes during 1 year of salvage therapy.
Patients and methods
Fifty-six patients with CD4 T cell counts ≤200/mm 3 , plasma HIV RNA .4 log 10 copies/mL and a genotypic score showing two or fewer active drugs were included and analysed in the randomized ETOILE ANRS 123 trial. 5 The study protocol was approved by the local ethics committee. All patients provided written informed consent. In brief, patients received either interleukin-2 (IL-2) combined with an optimized background therapy (OBT) or OBT alone as salvage treatment. OBT included enfuvirtide whenever possible. This trial showed that IL-2 failed to increase CD4 T cells whereas enfuvirtide use, even in a poor OBT, was associated with treatment success. 5 Our current analysis of HIV DNA levels is a substudy focusing on a non-random set of patients for whom blood cells were available at baseline and/or at week 52: there were 21 patients in the IL2+OBT arm and 23 patients with OBT alone at baseline, and 10 and 17 patients respectively at week 52. Blood cells were available at both week 0 and week 52 for 7 patients in the IL2+OBT arm and 14 in the OBT arm. HIV-1 DNA was quantified in whole blood using real-time PCR, as described previously. 6 The comparisons between groups and the correlations were assessed using x 2 , Wilcoxon and Pearson correlation coefficient tests, as appropriate. Correlations after adjustment were explored through a linear regression model. Any association between HIV DNA and CD4 T cell count change was assessed by logistic regression. Global type I error was equal to 0.05.
Results
Patients included in this substudy did not differ from other patients in baseline CD4 T cell count and HIV RNA load (data not shown).
In this substudy, patients from the two treatment arms had similar epidemiological characteristics [gender (P¼1.00), age (P¼0.26) and transmission risk group (P¼0.47)]. Baseline immunological and virological characteristics were as follows [median and interquartile range (IQR)]: CD4 T cell count, 47 (10-100) cells/mm 3 in the IL2+ OBT arm and 68 (26-107) cells/mm 3 in the OBT arm; HIV RNA, 5.1 (4.5-5.4) and 4.9 (4.4-5.1) log 10 copies/mL, respectively.
HIV DNA load at baseline [median (IQR)] was 3.44 (3.31 -4.08) log 10 copies/10 6 peripheral blood mononuclear cells (PBMCs) in the IL2 +OBT arm and 3.51 (3.18 -3.82) in the OBT arm. At week 52 it was 3.18 (2.75-3.52) and 3.48 (3.1 -3.67) log 10 copies/10 6 PBMCs, respectively. Change in HIV DNA load from baseline to week 52 was not correlated with IL-2 use, but decreased among the 7 patients receiving enfuvirtide (20.22 log 10 copies/10 6 PBMCs) as compared with the other 14 patients (+0.20) (P ¼ 0.046).
A steeper decrease of HIV DNA was observed among patients who had a larger increase in CD4 T cell count from baseline to week 52 (Pearson coefficient r¼0.659, P ¼0.001) (Figure 1 ). After adjustment for baseline HIV-1 RNA level, this correlation remained statistically significant (adjusted r¼0.682, P,0.001).
In contrast, the correlation became non-significant after adjustment for plasma HIV RNA change (r¼ 0.13, P¼ 0.58).
Finally, when considering all patients with an available HIV-1 DNA load, an upper baseline HIV-1 DNA level was associated, though not significantly, with a less frequent CD4 T cell gain ≥50 cells/mm 3 from W0 to W52 [the odds ratio (OR) adjusted for enfuvirtide use was 0.17 per 0.5 log 10 copies/10 6 PBMCs,
When considering adjustment for enfuvirtide use and baseline HIV-1 RNA level, the association of baseline HIV-1 DNA load with a gain of CD4 of more than 50 cells/mm 3 remained stable (adjusted OR¼ 0.20) but was not significantly associated with CD4 T cell gain (P¼ 0.14). When considering adjustment for enfuvirtide use and change of HIV RNA load, the association also remained stable (OR ¼ 0.24) but not statistically significant (P¼ 0.12). This may be due to the lack of power linked to the small number of patients included in this substudy.
Discussion
To our knowledge, these are the first data evaluating the blood cellular HIV-1 reservoir in immunocompromised patients with multiple therapeutic failures and high HIV RNA loads. One limitation of our study is that stored cells were not available for all patients enrolled in the ETOILE trial, reducing the power of our analysis though not generating a selection bias since baseline immunovirological characteristics did not differ according to inclusion in this substudy. HIV DNA levels are high in these patients with advanced therapeutic failure (median: 3.6 log 10 ) as compared with untreated patients recruited at the time of primary infection (median: 3.2 log 10 ) 7 or untreated patients during the asymptomatic chronic phase of HIV disease (median: 2.7 log 10 ). 8 The proportion of infected cells is at its highest during AIDS, when there is a profound CD4 T cell depletion.
We showed that an optimized background regimen, even if not highly active, allowed the blood HIV reservoir to decrease in these immunocompromised patients. HIV DNA did not change much from baseline to week 52, but this marker has lower amplitude than HIV RNA. Consequently, even low variations should be taken into account when there is a significant difference between groups. This low variation is in keeping with PBMCs after treatment for 1 year, 9 and 0.23 log 10 copies/10 6 PBMCs versus 0.55 log 10 copies/10 6 PBMCs respectively after treatment for 72 weeks). 10 Interestingly, we found an association between immune restoration and cellular HIV reservoir diminution, even after adjustment for baseline plasma HIV RNA load. The absence of significance after adjustment for plasma HIV RNA change was expected because HIV reservoir decrease is not independent of HIV RNA decrease.
Lastly, although this association warrants confirmation, our results suggest that a higher HIV-1 DNA load at baseline may be associated with a smaller change of CD4 T cell counts among patients with advanced therapeutic failure receiving OBT. A larger blood viral reservoir could thus be deleterious to immune restoration.
In conclusion, this study suggests that measurement of HIV-1 DNA, in addition to other HIV biomarkers, might be useful for case management in HIV-infected patients at late stages of disease.
